Barzolvolimab can eliminate hives and itch for about half of patients. What does Celldex need to prove before launch?
Celldex Therapeutics has delivered positive results from both Phase 3 EMBARQ studies of barzolvolimab in chronic spontaneous urticaria, with roughly 42% to 46% of treated patients completely free of hives and itch by Week 12 and response rates deepening through Week 24. The clinical programme also produced substantial activity after omalizumab failure and against angioedema,
